Effect of Food on the Pharmacokinetics of Rosuvastatin after Administration of a Single Oral Dose in Dogs

 

 Buy Article Permissions and Reprints

Abstract

Rosuvastatin is a highly effective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and is used for the treatment of patients with hyperlipidemia. We examined the effect of food on the pharmacokinetics of rosuvastatin by administering it while fasting and after intake of low-fat and high-fat meals. We administered a single 10-mg oral dose of rosuvastatin while fasting and after intake of a low-fat and high-fat meal in a parallel design. The plasma concentrations of rosuvastatin were measured using liquid chromatography tandem mass spectrometry (LC-MS/MS), and the pharmacokinetics of rosuvastatin was analyzed using both noncompartmental and compartmental models. The values of area under the curve at 24 h (AUC _{24   h} ) and peak plasma concentration (C _max) in fed conditions were significantly lower than the corresponding values in the fasting conditions. In addition, consumption of a high-fat meal significantly delayed the time required to achieve the maximum concentration (T _max) of rosuvastatin. Both the models sufficiently explained the effect of food on the pharmacokinetics of rosuvastatin and showed that the volume of distribution (V _c) was increased and absorption rate constant (K _a) was decreased in fed dogs. These findings suggest that food intake affects both the rate and extent of absorption of rosuvastatin, and that rosuvastatin should be administered on an empty stomach to avoid food effect.

^* Min-Soo Kim and Kwang-il Kwon have contributed equally to the work and provided equal resources to the project, and are co-corresponding authors.

• References

• 1 Simonson SG, Martin PD, Mitchell P et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol 2003; 58: 669-675
  PubMedGoogle Scholar
• 2 Martin PD, Dane AL, Nwose OM et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002; 42: 1116-1121
  CrossrefPubMedGoogle Scholar
• 3 McTaggart F, Buckett L, Davidson R et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87: 28B-32B
  PubMedGoogle Scholar
• 4 White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002; 42: 963-970
  CrossrefPubMedGoogle Scholar
• 5 US Food and Drug Administration. Website http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021366s024.pdf [11 Dec 2012]
  PubMed
• 6 Li Y, Jiang X, Lan K et al. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. Clin Ther 2007; 29: 2194-2203
  CrossrefPubMedGoogle Scholar
• 7 Lentz KA, Quitko M, Morgan DG et al. Development and validation of a preclinical food effect model. J Pharm Sci 2007; 96: 459-472
  CrossrefPubMedGoogle Scholar
• 8 Lentz KA. Current methods for predicting human food effect. AAPS J 2008; 10: 282-288
  CrossrefPubMedGoogle Scholar
• 9 Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19: 716-723
  CrossrefPubMedGoogle Scholar
• 10 D’Argenio DZ, Schumitzky A. ADAPT II User’s Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software, Biomedical Simulations Resource. Los Angeles. 1997
  PubMedGoogle Scholar
• 11 Fleisher D, Li C, Zhou Y et al. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 1999; 36: 233-254
  CrossrefPubMedGoogle Scholar
• 12 Ananthakrishnan R, Gona P. Pharmacological modeling and biostatistical analysis of a new drug. Open Access J Clin Trials 2010; 2: 59-82
  PubMedGoogle Scholar
• 13 Zimmermann T, Yeates RA, Laufen H et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994; 46: 147-150
  PubMedGoogle Scholar
• 14 Sjödin L, Visser S, Al-Saffar A. Using pharmacokinetic modeling to determine the effect of drug and food on gastrointestinal transit in dogs. J Pharmacol Toxicol Methods 2011; 64: 42-52
  CrossrefPubMedGoogle Scholar